Janux Therapeutics (NASDAQ:JANX) Posts Quarterly Earnings Results

Janux Therapeutics (NASDAQ:JANX) posted its quarterly earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13, Zacks reports. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded down $0.59 during midday trading on Thursday, reaching $32.01. The company’s stock had a trading volume of 425,092 shares, compared to its average volume of 1,022,335. The stock has a market capitalization of $1.68 billion, a P/E ratio of -27.36 and a beta of 3.16. The stock’s 50-day simple moving average is $44.72 and its 200-day simple moving average is $47.95. Janux Therapeutics has a 52-week low of $31.69 and a 52-week high of $71.71.

Analyst Upgrades and Downgrades

JANX has been the topic of several recent research reports. HC Wainwright increased their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners increased their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Scotiabank boosted their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Finally, Stifel Nicolaus boosted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $89.90.

Insider Transactions at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now owns 217,054 shares in the company, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,668 shares of company stock worth $3,582,515. Insiders own 29.40% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.